You are using IE 8 or below so some features may not work. Please upgrade to a modern browser
Ihr Webbrowser ist veraltet und wird leider nicht in vollem Umfang unterstützt.



Method and device for producing lipid vesicles
granted by: AU 2002215987; CA 2,427,640; EP 1337322; US 6,843,942

Application of superoxide dismutase in liposomes
granted by: AU 690377; CA 2,204,493; EP 0789584; MX 206295; NZ 296098; US 5,942,245; US 6,312,720

Superloaded liposomes for drug delivery
granted by: AU 2005247091; CA 2,567,961; CN 1960706A; EA 200602172; EP 1748760; IN 244478; KR 1212377

Liposomal composition comprising an active ingredient for relaxing smooth muscle production and therapeutically use of said composition
granted by: AU 04024753.8; CA 2,583,332; EA 011391; EP 1802277; JP 5688199; KR 1289917; NZ 554183; US 8,524,274


Suleiman E, Damm D, Batzoni M, Temchura V, Wagner A, Überla K, Vorauer-Uhl K (2019)Electrostatically Driven Encapsulation of Hydrophilic, Non-Conformational Peptide Epitopes into Liposomes. Pharmaceutics 11(11), 619

Bolger GT, Licollari A, Bagshaw R, Tan A, Greil R, Vcelar B, Majeed M, Sordillo P (2019) Intense Uptake of Liposomal Curcumin by Multiple Myeloma Cell Lines: Comparison to Normal Lymphocytes, Red Blood Cells and Chronic Lymphocytic Leukemia Cells. Anticancer Res 39(3):1161-1168

Bolger GT, Licollari A, Tan A, Greil R, Vcelar B, Greil-Ressler S, Weiss L, Schönlieb C, Magnes T, Radl B, Majeed M, Sordillo PP (2019) Pharmacokinetics of liposomal curcumin (Lipocurc™) infusion: effect of co-medication in cancer patients and comparison with healthy individuals. Cancer Chemother Pharmacol 83(2):265-275

Greil R, Greil-Ressler S, Weiss L, Schönlieb C, Magnes T, Radl B, Bolger GT, Vcelar B, Sordillo PP (2018) A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc™) in patients with locally advanced or metastatic cancer. Cancer Chemother Pharmacol 82(4):695-706

Bolger GT, Licollari A, Tan A, Greil R, Pleyer L, Vcelar B, Majeed M, Sordillo P (2018) Distribution of Curcumin and THC in Peripheral Blood Mononuclear Cells Isolated from Healthy Individuals and Patients with Chronic Lymphocytic Leukemia. Anticancer Res 38(1):121-130

Bolger GT, Licollari A, Tan A, Greil R, Vcelar B, Majeed M, Helson L (2017) Distribution and Metabolism of Lipocurc™ (Liposomal Curcumin) in Dog and Human Blood Cells: Species Selectivity and Pharmacokinetic Relevance. Anticancer Res 37(7):3483-3492

Kloesch B, Gober L, Loebsch S, Vcelar B, Helson L, Steiner G (2016) In Vitro Study of a Liposomal Curcumin Formulation (Lipocurc™): Toxicity and Biological Activity in Synovial Fibroblasts and Macrophages. In Vivo 30(4):413-9

Storka A, Vcelar B, Klickovic U, Gouya G, Weisshaar S, Aschauer S, Bolger G, Helson L, Wolzt M (2015) Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans. Int J Clin Pharmacol Ther 53(1):54-65

Koutsoulas C, Suleiman E, Wagner A, Žabka M (2014) Comparative study between synthetic and phospholipids of natural origin: effect of phospholipid selection on the behaviour of a topical liposomal dosage form incorporating terbinafie. J Liposome Res 24(4):336-43

Rodrigueza WV, Woolliscroft MJ, Ebrahim AS, Forgey R, McGovren PJ, Endert G, Wagner A, Holewa D, Aboukameel A, Gill RD, Bisgaier CL, Messmann RA, Whitehead CE, Izbicka E, Streeper R, Wick MC, Stiegler G, Stein CA, Monsma D, Webb C, Sooch MP, Panzner S, Mohammad R, Goodwin NC, Al-Katib A (2014) Development and antitumor activity of a BCL-2 targeted single-stranded DNA oligonucleotide. Cancer Chemother Pharmacol 74(1):151-66

Storka A, Vcelar B, Klickovic U, Gouya G, Weisshaar S, Aschauer S, Helson L, Wolzt M (2013) Effect of liposomal curcumin on red blood cells in vitro. Anticancer Res 33(9):3629-34

Katinger D, Wagner A, Luque I, Crespillo S, Conejero-Lara F, Roger M, Martin C, Mouz N, Mourao S, Farsang A, Notka F, Malcolm K, Bosquet N, Le Grand R, Moog C, Cope A, Shattock R, Lewis DJ, El Habib R (2012) Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans. Retrovirology 9 (Suppl 2):354

Birnbaumer G, Küpcü S, Jungreuthmayer C, Richter L, Vorauer-Uhl K, Wagner A, Valenta C, Sleytr U, Ertl P (2011) Rapid liposome quality assessment using a lab-on-a-chip. Lab Chip. 11(16):2753-62

Wagner A, Vorauer-Uhl K (2011) Liposome Technology for Industrial Purposes. Journal of Drug Delivery 2011, 9 pages

Wagner A, Stiegler G, Vorauer-Uhl K, Katinger H, Quendler H, Hinz A, Weissenhorn W (2007) One Step Membrane Incorporation of Viral Antigens as a Vaccine Candidate Against HIV. J Liposome Res 17(3):139-54

Wagner A, Platzgummer M, Kreismayr G, Quendler H, Stiegler G, Ferko B, Vecera G, Vorauer-Uhl K, Katinger H (2006) GMP Production of Liposomes-A New Industrial Approach. J Liposome Res 16(3):311-9

Vorauer-Uhl K, Wagner A, Borth N, Katinger H (2002) Long term stability of rh-Cu/Zn-SOD-liposomes prepared by the crossflow injection technique following ICH-guidelines. European Journal of Pharmaceutics and Biopharmaceutics 54:77-81

Wagner A, Vorauer-Uhl K, Kreismayr G, Katinger H (2002) Enhanced protein loading into liposomes by the multiple injection technique. Journal of Liposome Research 12(3):271-83

Wagner A, Vorauer-Uhl K, Kreismayr G, Katinger H (2002) The crossflow injection technique - an improvement of the ethanol injection method. Journal of Liposome Research 12(3):259-70

Wagner A, Vorauer-Uhl K, Katinger H (2002) Liposome produced in a pilot scale: production, purification and efficiency aspects. European Journal of Pharmaceutics and Biopharmaceutics 54:213-9


October 25-28, 2020

Boston, MA, USA

Dr. Andreas Wagner


Polymun Liposome Technology 
Broschure (pdf, 1MB)